Issue 64, 2016

Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease

Abstract

An indomethacin-guided drug delivery conjugate (IGDDC) has been designed by utilizing cancer associated elevated HDAC and CTSL activities as consecutive demasking ventures for drug activation. IGDDC exhibited preferential uptake by COX-2 positive cells both in vitro and ex vivo highlighting indomethacin’s role in designing new cancer-specific drug delivery frameworks.

Graphical abstract: Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease

Supplementary files

Article information

Article type
Communication
Submitted
20 May 2016
Accepted
08 Jul 2016
First published
08 Jul 2016

Chem. Commun., 2016,52, 9965-9968

Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease

J. H. Jang, H. Lee, A. Sharma, S. M. Lee, T. H. Lee, C. Kang and J. S. Kim, Chem. Commun., 2016, 52, 9965 DOI: 10.1039/C6CC04255D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements